Medical and health | the first domestic novel coronavirus vaccine approved by who| Seizing the fourth terminal, the pharmaceutical industry joins the new strategic track

   Some time ago, the Chinese government website released the opinions of the general office of the State Council on the “six stabilities” and “six guarantees” of service and the further improvement of the reform of “release, management and service”, which clearly put forward: “on the premise of ensuring the authenticity and reliability of the source of electronic prescriptions, It is allowed to sell prescription drugs on the Internet other than those under special state administration

.

” This marks the official lifting of the ban on online prescription drugs in China

.

Online sales of Chinese medicine has been irreversibly moving towards full recognition, full compliance and conditional opening

.

The opening of online sales of prescription drugs is a great progress

.

So far, China’s pharmaceutical field has entered the fourth terminal era

.

   Guangzhou Daily 2021-05-08 Guangdong has a unified catalog of medical insurance drugs, diagnosis and treatment items and medical consumables! Since August 15, Guangdong has officially implemented the unified medical treatment items and medical consumables catalogue managed by the access law in the whole province, “extracorporeal membrane lung support”, psychotherapy, preventive treatment items, rehabilitation training for children with cerebral palsy and autism and other aspects that have attracted much social attention have been included in the medical insurance payment

.

   Fosun Pharmaceutical plans to establish a joint venture to produce the new mRNA crown vaccine in China

.

The new mRNA crown vaccine developed by Fosun Pharmaceutical and biontech of Germany has not been approved for use in the mainland of China, but both sides plan to produce the vaccine in China

.

On the evening of May 9, Fosun Pharmaceutical announced that the holding subsidiary Fosun Pharmaceutical industry plans to set up a joint venture with biontech to realize the localized production and commercialization of mRNA new coronal vaccine products

.

The term of the joint venture is 15 years from the date of establishment, and the initial place of establishment is Shanghai, China

.

   Pfizer / biontech submitted the application for mRNA vaccine to FDA on a rolling basis

.

On May 8, Pfizer / biontech jointly announced that it has started to submit the application for biological product license (BLA) for mRNA vaccine bnt162b2 (tozinameran) to FDA on a rolling basis to prevent the infection of covid-19 in people aged 16 and above

.

BLA application materials will be submitted in the next few weeks, and the two companies have also submitted priority review applications to FDA

.

   hot wire! The first domestic novel coronavirus vaccine approved by who! The wechat public platform dingxiangyuan 2021-05-08 late last night, who announced that the novel coronavirus vaccine developed by Beijing Institute of biological products of Sinopharm group (bbibp-corv, hereinafter referred to as Sinopharm Beijing vaccine) was included in the emergency use list

.

This is the sixth vaccine listed in the emergency use list (Eul) by who in the world

.

The first five vaccines are Pfizer vaccine, Pfizer vaccine and Sinopharm Beijing vaccine Two doses of Oxford vaccine (Korean version and Indian version), Johnson & Johnson vaccine and Moderna vaccine

.

   AstraZeneca tremelimumab triple therapy is effective in the first-line treatment of stage IV NSCLC

.

Sina medical news website 2021-05-085 AstraZeneca said that adding imminzi and tremelimumab to chemotherapy can significantly prolong the life of patients with newly diagnosed stage IV or metastatic non-small cell lung cancer (NSCLC)

.

The company said the improvement was clinically significant, but did not provide detailed data

.

In addition, the survival rates of the imminzi + chemotherapy group and the chemotherapy alone group were not statistically significant, which means that tremelimumab does play a role in the triple therapy

.

   Enter 9.6 billion market! On May 7, 2021-09, Shandong new era pharmaceutical pegylated recombinant human granulocyte stimulating factor injection was approved by nmpa, becoming the fourth domestic long-acting Shengbai drug

.

Granulocyte colony stimulating factor (G-CSF) is a glycoprotein, which can bind to specific receptors on the surface of granulocyte progenitor cells or mature neutrophils, promote the proliferation and differentiation of granulocyte progenitor cells, and enhance the phagocytosis and killing ability of neutrophils

.

This drug is one of the most commonly used adjuvant drugs in tumor chemotherapy

.

It can also be used for mobilization of hematopoietic stem cells in bone marrow transplantation, reconstruction of bone marrow hematopoietic function after transplantation, and improvement of neutropenia caused by myelodysplastic syndrome or myelodysplastic syndrome

.

   First line treatment prolongs the life of lung cancer patients, and triple combination therapy of AstraZeneca has reached the clinical end point of phase 3

.

Wechat public platform – yaomingkang 2021-05-08 today, AstraZeneca announced that its triple combination therapy composed of anti-PD-L1 monoclonal antibody imminzi (durvalumab) and anti-CTLA-4 antibody tremelimumab combined with chemotherapy, The primary and key secondary endpoints were achieved in the phase 3 trial Poseidon for the first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC)

.

Compared with chemotherapy alone, the triple combination therapy has a statistically significant and clinically significant improvement in overall survival (OS)

.

This is the first time tremelimumab has shown an overall survival benefit in a phase 3 clinical trial

.

   Keytruda + lenvima has been given priority review by FDA for the treatment of renal cell carcinoma and endometrial carcinoma

.

Wechat public platform for the treatment of renal cell carcinoma and endometrial carcinoma – Magic Cube info2021-05-08 on May 6, Merck and Weicai announced that FDA has granted keytruda + lenvima priority review qualification for the treatment of patients with advanced renal cell carcinoma (RCC) and endometrial carcinoma

.

PDUFA is scheduled to be approved on August 25 and September 3, respectively

.

   On May 7, 2021-05-08, according to the official website of CDE, the listing application of Beijing lenoki Pharmaceutical Technology (a subsidiary of shengnuoji) acoradine soft capsule has been accepted by the State Food and Drug Administration and will be included in the priority review, It is used to treat unresectable hepatocellular carcinoma without systemic treatment

.

   Third in China! Bo’an biological bevacizumab injection (boyuno) has been approved for listing in China

.

Wechat public platform medicine Rubik’s cube 2021-05-08 LVYE Pharmaceutical Group announced that its holding subsidiary bo’an biological bevacizumab injection (boyuno) has been approved for listing in China ®) It has been officially approved by the State Drug Administration of China for the treatment of advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer

.

Boyuno ® It is the third approved avidin in China ®( Avastin ®) It is also the first product of Boan biological series to be approved for marketing

.

   On May 7, 2021-08, virogin biotech Limited announced that it had won the D1 round financing of US $80 million.

.